Amisulpride Rescue Dosing After Failed PONV Prophylaxis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for postoperative nausea and vomiting (PONV) fail to adequately address the technical problem of existing technologies have not addressed the technical problem of existing technologies have not addressed the technical problem of existing technologies in effectively reducing PONV in patients who have received prior prophylaxis, with current standard-of-care drugs like 5HT3 antagonists showing limited efficacy.

Innovation Solution

Amisulpride, particularly at a dose of 10 mg, is administered as a rescue treatment for PONV in patients who have already received unsuccessful prophylaxis, offering a different mechanism of action to reduce nausea and vomiting.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If standard prophylaxis drugs like 5HT3 antagonists are administered, then PONV prevention is attempted, but efficacy is limited and PONV still occurs in 30-40% of cases

Engineering Contradiction:

Improveefficacy of PONV prophylaxisVSAvoideffectiveness in patients who failed prior prophylaxis

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the pharmacological parameter by switching from 5HT3 antagonists to amisulpride, a dopamine D2 receptor antagonist with different mechanism of action. This parameter change enables effective treatment in patients who failed standard prophylaxis, achieving 60% success rate in rescue treatment compared to 30-40% failure rate with continued standard therapy.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If amisulpride 5 mg is administered as rescue treatment, then some PONV relief is achieved, but efficacy is suboptimal compared to higher doses

Engineering Contradiction:

Improveefficacy of rescue treatmentVSAvoidamisulpride dose

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent identifies and implements the optimal dosage parameter for amisulpride in rescue treatment. Clinical trials demonstrated that 10 mg dose achieves 60% success rate, significantly outperforming 5 mg dose, establishing 10 mg as the optimal therapeutic parameter for PONV rescue treatment.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If multiple anti-emetic agents are used in combination, then PONV coverage is expanded, but device complexity and treatment regimen complexity increase

Engineering Contradiction:

Improvecoverage of PONV mechanismsVSAvoidcomplexity of treatment regimen

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent positions amisulpride as a universal rescue treatment that addresses multiple PONV mechanisms through its dopamine antagonism. It effectively treats PONV regardless of the specific mechanism involved (serotonin release, chemoreceptor trigger zone activation), providing multi-functional coverage in a single agent without requiring complex combination regimens.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250367211A1Rescue treatment of post operative nausea and vomiting

Publication Date: 2025.12.04 LXO IRELAND DESIGNATED ACTIVITY CO

AI summary

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.